-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TuDH8+e8z4mPxNd2rz6zNV/mkrfhR7VVckD68SAFX8UUg3ZLLLhKou4YM5WM98kH PObRedbw+R1c3lCLTLHpsA== 0001144204-06-052981.txt : 20061215 0001144204-06-052981.hdr.sgml : 20061215 20061215170724 ACCESSION NUMBER: 0001144204-06-052981 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20061212 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20061215 DATE AS OF CHANGE: 20061215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: COLUMBIA LABORATORIES INC CENTRAL INDEX KEY: 0000821995 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 592758596 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-10352 FILM NUMBER: 061281233 BUSINESS ADDRESS: STREET 1: 354 EISENHOWER PARKWAY CITY: LIVINGSTON STATE: NJ ZIP: 07039 BUSINESS PHONE: 9739943999 MAIL ADDRESS: STREET 1: 354 EISENHOWER PARKWAY CITY: LIVINGSTON STATE: NJ ZIP: 07039 8-K 1 v060494_8k.htm

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
 

 
DATE OF REPORT - December 12, 2006
(Date of Earliest Event Reported)
 
COLUMBIA LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
 
Commission File No. 1-10352

 
Delaware
 
59-2758596
(State of Incorporation)
 
(I.R.S. Employer Identification No.)
     
354 Eisenhower Parkway
Livingston, New Jersey
 
 
07039
(Address of principal executive offices)
 
Zip Code

 
Registrant’s telephone number, including area code: (973) 994-3999
 
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



 
 

 

Item 1.01. Entry into a Material Definitive Agreement.

Separation Agreement with David L. Weinberg.

On December 12, 2006, Columbia Laboratories, Inc. (the “Company”) and David L. Weinberg, the Company’s former Vice President, Chief Financial Officer, and Treasurer, entered into a separation agreement and general release of claims (the “Separation Agreement”), pursuant to which the Company has agreed to pay Mr. Weinberg, as a severance payment, $212,000, in twenty-four consecutive bi-monthly payments beginning on January 15, 2007 (the “Severance Payment”). In addition to the Severance Payment, the Company has agreed to extend the exercise period for Mr. Weinberg’s vested stock option grants until their original dates of expiration (the “Extended Exercise Period”). The Company will incur a non-cash charge to earnings in the current quarter for the difference between the average of the high and low prices of the Company’s stock on December 12, 2006, and the exercise price of Mr. Weinberg’s in-the-money options. The charge will be approximately $100,000. Mr. Weinberg has agreed to be available for consultation with the Company. In consideration for the Severance Payment and the Extended Exercise Period, Mr. Weinberg also agreed to release the Company from any claims he may have against the Company. The foregoing description is qualified by reference to the Separation Agreement filed as Exhibit 10.67 to this Current Report on Form 8-K. 
 

 
 

 

Item 9.01 Financial Statements and Exhibits.
 
(a) Not applicable
 
(b) Not applicable
 
(c) Not applicable
 
(d) Exhibits.
 
Exhibit No.
Description
10.67
Separation Agreement by and between Columbia Laboratories, Inc. and David L. Weinberg effective as of December 12, 2006

 

 
 

 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: December 15, 2006
 

 
COLUMBIA LABORATORIES, INC.
 
By: /S/ Michael McGrane
Michael McGrane
Senior Vice President, General Counsel
and Secretary
 

 
 

 

EXHIBIT INDEX

Exhibit No.
Description
10.67
Separation Agreement by and between Columbia Laboratories, Inc. and David L. Weinberg effective as of December 12, 2006

 
EX-10.67 2 v060494_ex10-67.htm

Exhibit 10.67
 
Separation Agreement and General Release of Claims
 
Severance Benefit

In return for the execution of this Separation Agreement and General Release, I, David L. Weinberg (referred to below as “I”, “me”, “my” or the “Employee”) will receive a separation payment to which I am not otherwise entitled that is equal to my annual base salary in effect on the date hereof. My separation payment, less applicable deductions, will be paid out in twenty-four (24) equal payments over twelve months, beginning January 15, 2007. In further return for my execution of this Separation Agreement and General Release, my stock option grants numbered 440, 522, 523, 630, 761, 824, 919, 907, and 920 that are vested on December 31, 2006, will remain exercisable until their original dates of expiration and I will have the full term from the time of the grant in order to exercise all vested awards (subject to termination based on the applicable plan provisions other than those related to termination of employment).

This Separation Agreement and Release of Claims will be effective on the later date of the signatures below.

In consideration of the receipt of the Severance Benefit described above, I agree as follows:

1.
Company Obligations

Other than as set forth in the attached letter, the Company shall have no other financial obligations to me under any compensation or benefit plan, program or policy and my participation in the Company compensation and benefit plans, programs and policies shall cease as of December 31, 2006, except that: (1) I shall have such right to continue group health plan coverage as is provided under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”) or a comparable state law; and (2) this Separation Agreement and General Release is not intended to cover any claim for benefits to which I am entitled, if any, under the Company’s 401(k) Plan.
 
2.
Cooperation

From time to time the Company finds it necessary or advisable to contact former employees to discuss matters about which they might have knowledge that are relevant to ongoing matters of the Company or otherwise related to their employment period. Accordingly, I agree that I will cooperate in all reasonable respects and generally make myself available to speak with Company employees and counsel, give testimony, and provide assistance in connection with any matter that relates to my employment period, including litigation, arbitration proceedings, government hearings or investigations involving the Company, or any other matter, provided that with regard to matters not involving litigation or potential litigation, this provision shall not apply after one (1) year from the date hereof. The Company will, to the extent feasible, use reasonable business efforts to limit itself to telephonic and email inquiries of a total of four (4) or fewer hours per week during the initial three months of this agreement and otherwise provide me with reasonable notice in the event my assistance is required. In connection with any cooperation where the Company requires me to be available in person, the Company will reimburse me for my reasonable travel, meal and lodging expenses. My entitlement to reimbursement of expenses pursuant to this paragraph 16 shall in no way affect other rights I may have to be indemnified and/or advanced expenses, provided that in no event shall there be any duplication of indemnification and/or expense reimbursement. I will not be entitled to any other compensation for cooperation, except as otherwise provided under my Indemnification Agreement with the Company dated April 8, 2004.

 
 

 
3.
Release of Claims

 
A.
In exchange for the consideration described above, I agree to release and forever discharge the Company, its subsidiaries and affiliates and their parent organizations, predecessors, successors, officers, directors, employees, agents, attorneys, associates, and employee benefit plans from all claims, demands or causes of action arising out of facts or occurrences prior to the date of this Agreement, whether known or unknown to me, between the Company and me.

 
B.
I agree that this release of claims is intended to be broadly construed so as to resolve any pending and potential disputes between the Company and me that I have up to the date of this Release, whether or not such disputes are known or unknown to me, including, but not limited to, claims based on express or implied contract; any action arising in tort, including, but not limited to, libel, slander, defamation, intentional infliction of emotional distress, or negligence; any and all claims for wrongful discharge; and any and all claims based on the Age Discrimination in Employment Act (42 U.S.C. § 621), Title VII of the Civil Rights act of 1964 as amended (42 U.S.C. § 2000e), the Equal Pay Act of 1963 (29 U.S.C. § 206(d)), the Civil Rights Acts of 1866 and 1871 (42 U.S.C. § 1981), the Worker Adjustment and Retraining Notification Act (29 U.S.C. § 1651), the Employee Retirement Income Security Act (29 U.S.C. § 1001), the Family and Medical Leave Act (29 U.S.C. §2601), the Americans with Disabilities Act (42 U.S.C. § 12,101), the Occupational Safety and Health Act (29 U.S.C. § 651), or any other federal, state or local statute prohibiting discrimination on the basis of age, race, creed, color, religion, national origin, sex, disability, marital status or any other protected classification which I have, or at any time had, including but not limited to all claims for attorneys fees..

 
C.
If I breach or challenge the enforceability of this Agreement, I acknowledge that I will reimburse the Company for any monetary consideration previously received by me under this Agreement and agree to pay reasonable attorneys’ fees and costs incurred by the Company in collection and enforcement of this Agreement; provided that this paragraph shall have no application to me with respect to a claim asserting that my separation was due to unlawful age discrimination in violation of the Age Discrimination in Employment Act.

 
 

 
 
4.
Non-Admission of Liability

This General Release shall not in any way be construed as an admission by the Company that it has acted wrongfully with respect to me or any other person, or that I have any rights whatsoever against the Company, and the Company specifically denies any liability to or wrongful acts against me or any other person, on the part of itself, its employees and its agents.

5.
Additional Understandings

A. I acknowledge and agree as follows:

 
(1)
The payments and other benefits provided to me under this Agreement exceed the nature and scope of that to which I would otherwise have been entitled to receive from the Company and constitute adequate consideration for my promises herein;

 
(2)
I agree that on or before my last work day with the Company, I will return to the Company all notes, reports, plans, keys, security cards and/or identification cards, charge cards, customer and investor lists, computer or other files, passwords, product information and other documents and property which were created, developed, generated or received by me during my employment or which are the property of the Company, whether or not such items are confidential to the Company.

 
(3)
I acknowledge that, before signing this Release, I was given a period of at least twenty-one (21) calendar days to consider this Release and I waive any right I might have to additional time beyond this twenty-one (21) day consideration period within which to consider this Release;

 
(4)
I have read and understand this Agreement in its entirety, including the waiver of rights under the Age Discrimination in Employment Act;

 
(5)
I have been advised by the Company to consult with an attorney before signing this Agreement and this paragraph constitutes such advice in writing;

 
(6)
For a period of seven (7) days following my execution of this Agreement, I may revoke this Agreement by notifying Rosemary Bergamo, Columbia Laboratories, Inc., 354 Eisenhower Parkway, Livingston, NJ, and it shall not become effective or enforceable until the 7-day revocation period has expired;

 
(7)
I enter into this Agreement knowingly and voluntarily, without duress or reservation of any kind, and after having given the matter full and careful consideration.

 
 

 
 
B.
Nothing in this Agreement shall be construed to prohibit me from filing any charge or complaint with the Equal Employment Opportunity Commission (EEOC) or participating in any investigation or proceeding conducted by the EEOC, nor shall any provision of this Agreement adversely affect my right to engage in such conduct. Notwithstanding the foregoing, I intend that the Company shall have the right, to the full extent permitted by law, to enforce this Agreement and to pursue any and all legal or equitable remedies against me in the event I violate this Agreement.

6.
No Representations

I represent and acknowledge that in executing this document, I do not rely and have not relied upon any representation or agreement not set forth in this Separation Agreement and General Release with regard to its subject matter, basis or effect.

7.
Severability

The provisions of this Separation Agreement and General Release are severable, and if any part is found to be unenforceable, the other paragraphs shall remain fully valid and enforceable.

8.
Governing Law

This Separation Agreement and General Release will be construed under the law of the State of New Jersey and, where applicable, under federal law.

PLEASE READ CAREFULLY. THIS SEPARATION AGREEMENT AND GENERAL RELEASE INCLUDES A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS.
 

/S/ David L. Weinberg
12/11/06
Signature: David L. Weinberg
(Date)


Columbia Laboratories, Inc.


/S/ Robert S. Mills
12/12/06
Signature: Robert S. Mills
(Date)

 
-----END PRIVACY-ENHANCED MESSAGE-----